
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. (HRMY) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · HRMY · as of Jun 8, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
8
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
Harmony Biosciences Holdings, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 8, 2026
HRMY insider buying and selling by quarter
HRMY insider selling · HRMY insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 8, 2026
Active insiders
Most active in past 12 months · HRMY ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
HRMY executive sell shares · HRMY board member insider trading · HRMY insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 18,750 | — | Form 4 |
| May 1, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 8,882 | $283K | Form 4 |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Option | 7,500 | — | Form 4 |
| Apr 7, 2026 | Zaeske Adam H. CHIEF COMMERCIAL OFFICER | Other | 3,173 | $88K | Form 4 |
| Jan 26, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 3,746 | $139K | Form 4 |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 4,725 | — | Form 4 |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 3,813 | — | Form 4 |
| Jan 25, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Other | 2,553 | $94K | Form 4 |
| Jan 24, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Other | 2,239 | $82K | Form 4 |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option | 2,600 | — | Form 4 |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Option | 2,500 | — | Form 4 |
| Jan 25, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Other | 1,126 | $41K | Form 4 |
| Jan 24, 2026 | Serafin Andrew CHIEF STRATEGY OFFICER | Other | 1,116 | $41K | Form 4 |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 2,662 | — | Form 4 |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Option | 2,188 | — | Form 4 |
| Jan 25, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 1,372 | $51K | Form 4 |
| Jan 24, 2026 | Budur Kumar CHIEF MEDICAL OFFICER | Other | 1,153 | $42K | Form 4 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 13,000 | — | Form 4 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 10,500 | — | Form 4 |
| Jan 25, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Other | 5,654 | $208K | Form 4 |
| Jan 24, 2026 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Other | 4,785 | $176K | Form 4 |
| Jan 15, 2026 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Sale | 20,961 | $753K | Form 4 |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Option | 20,000 | $164K | Form 4 |
| Dec 12, 2025 | Dayno Jeffrey M. PRESIDENT, CEO · Director | Sale | 5,933 | $238K | Form 4 |
| Dec 5, 2025 | Kapadia Sandip CHIEF FINANCIAL OFFICER | Option | 20,000 | $581K | Form 4 |
Budur Kumar
CHIEF MEDICAL OFFICER
Date
May 1
Shares
8,882
Price
$31.83
Value
$283K
Zaeske Adam H.
CHIEF COMMERCIAL OFFICER
Date
Apr 7
Shares
3,173
Price
$27.62
Value
$88K
Kapadia Sandip
CHIEF FINANCIAL OFFICER
Date
Jan 26
Shares
3,746
Price
$37.15
Value
$139K
Kapadia Sandip
CHIEF FINANCIAL OFFICER
Date
Jan 25
Shares
2,553
Price
$36.82
Value
$94K
Kapadia Sandip
CHIEF FINANCIAL OFFICER
Date
Jan 24
Shares
2,239
Price
$36.82
Value
$82K
Serafin Andrew
CHIEF STRATEGY OFFICER
Date
Jan 25
Shares
1,126
Price
$36.82
Value
$41K
Serafin Andrew
CHIEF STRATEGY OFFICER
Date
Jan 24
Shares
1,116
Price
$36.82
Value
$41K
Budur Kumar
CHIEF MEDICAL OFFICER
Date
Jan 25
Shares
1,372
Price
$36.82
Value
$51K
Budur Kumar
CHIEF MEDICAL OFFICER
Date
Jan 24
Shares
1,153
Price
$36.82
Value
$42K
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Jan 25
Shares
13,000
Price
—
Value
—
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Jan 24
Shares
10,500
Price
—
Value
—
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Jan 25
Shares
5,654
Price
$36.82
Value
$208K
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Jan 24
Shares
4,785
Price
$36.82
Value
$176K
Kapadia Sandip
CHIEF FINANCIAL OFFICER
Date
Jan 15
Shares
20,961
Price
$35.92
Value
$753K
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Dec 12
Shares
20,000
Price
$8.22
Value
$164K
Dayno Jeffrey M.
PRESIDENT, CEO · Director
Date
Dec 12
Shares
5,933
Price
$40.11
Value
$238K
Kapadia Sandip
CHIEF FINANCIAL OFFICER
Date
Dec 5
Shares
20,000
Price
$29.03
Value
$581K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About HRMY insider trading
HRMY insider trades
Harmony Biosciences Holdings, Inc. (HRMY) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Kapadia Sandip (CHIEF FINANCIAL OFFICER), Budur Kumar (CHIEF MEDICAL OFFICER), Dayno Jeffrey M. (PRESIDENT, CEO · Director). Over the past 12 months, 5 insiders have filed transactions with the SEC. HRMY insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Harmony Biosciences Holdings, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
HRMY insider trading · 5 questionsThe insiders of Harmony Biosciences Holdings, Inc. (HRMY) include executives and directors such as Kapadia Sandip (CHIEF FINANCIAL OFFICER), Budur Kumar (CHIEF MEDICAL OFFICER), Dayno Jeffrey M. (PRESIDENT, CEO · Director), among others. Over the past 12 months, 5 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 8, 2026